MetaCap

AN2 Therapeutics (ANTX) vs Faeth Therapeutics (FTH)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

AN2 Therapeutics (ANTX) has outperformed Faeth Therapeutics (FTH) over the past year, gaining 366.1% versus a loss of 9.6%. Faeth Therapeutics is the larger company by market cap ($203.7 million vs $192.8 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ANTX+366.06%FTH-9.64%
+500%+233%-34%
Nov 21, 20251 yearNov 20, 2026
ANTX-67.01%FTH-83.02%
+42%-29%-100%
Mar 21, 20225 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ANTX versus FTH key metrics
MetricANTXFTH
Share price$5.08$7.88
Market cap$192.75M$203.65M
1-day change-2.68%-9.32%
YTD return+345.61%-26.15%
1-year return+366.06%-9.64%
5-year return—-94.96%
EPS (TTM)$-0.91$-22.50
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Net income (latest FY)$-35.17M$-21.09M
52-week high$7.19$42.14
52-week low$1.00$7.45
Distance from 52-week high-29.35%-81.30%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+77.17%+612.56%
Average volume289.29K500.25K
Shares outstanding37.94M25.84M
Employees2129
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • ANTX has outperformed FTH by 375.7 percentage points over the past year.

About AN2 Therapeutics

ANTX stock →

AN2 Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics. The company's initial candidate includes epetraborole, which is phase 3 clinical trial as a once-daily oral treatment for patients with non-tuberculous mycobacterial lung disease, as well as studying for the treatment of acute melioidosis.

Health Care · Biotechnology: Pharmaceutical Preparations · 21 employees

About Faeth Therapeutics

FTH stock →

Faeth Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of therapeutics for cancer patients. The company offers PIKTOR, an investigational multi-node inhibitor of the PI3K/AKT/mTOR pathway in development for endometrial and breast cancer.

Health Care · Biotechnology: Pharmaceutical Preparations · 29 employees

ANTX vs FTH FAQ

Which is bigger, AN2 Therapeutics or Faeth Therapeutics?

Faeth Therapeutics (FTH) is larger, with a market capitalization of $203.65M compared with $192.75M for AN2 Therapeutics (ANTX).

Which stock has performed better over the past year, ANTX or FTH?

ANTX returned +366.06% over the past 12 months, compared with -9.64% for FTH (price return, excluding dividends). Past performance does not predict future results.

Are AN2 Therapeutics and Faeth Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons